Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making.

Cancer treatment reviews - 1 May 2026

Zhao Shengliang, Liu Xiaoqing, Wang Jingsi, Tang Bo, Long Qin, Tang Xingwei, Dai Jigang, Jiang Yingjiu, Liu Quanxing

Abstract excerpt

The management of resectable non-small cell lung cancer (NSCLC) with EGFR-sensitizing mutations has changed substantially over the past decade, with adjuvant osimertinib now representing the most mature perioperative strategy because it has demonstrated durable disease-free survival, overall survival, and central nervous system (CNS) benefit in ADAURA. This review examines resectable EGFR-mutant NSCLC through the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Clinical Decision-Making

Share to Indoles

Share to Neoadjuvant Therapy

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 42033967
DOI: 10.1016/j.ctrv.2026.103138

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making.PMID 42033967Read ↗

Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.Semantic proximity Read ↗

Perioperative targeted therapy for oncogene-driven NSCLC.Semantic proximity Read ↗

Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: Current Strategies and Unanswered Questions.Semantic proximity Read ↗

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Comprehensive Review.Semantic proximity Read ↗

Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers.Semantic proximity Read ↗

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.Semantic proximity Read ↗

Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.Semantic proximity Read ↗

Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits.Semantic proximity Read ↗

Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?Semantic proximity Read ↗

EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.